Stocks & Investing
Tue, February 28, 2023
[ 12:00 AM ] - WOPRAI
Tue, January 23, 2018
Thu, November 9, 2017
[ 12:00 AM ] - WOPRAI
Mon, November 6, 2017
[ 12:00 AM ] - WOPRAI
Thu, February 23, 2017
[ 12:00 AM ] - WOPRAI
Wed, October 19, 2016
Wed, September 28, 2016
[ 12:00 AM ] - WOPRAI
Thu, July 14, 2016
Fri, April 22, 2016
[ 12:00 AM ] - WOPRAI
Mon, April 11, 2016
[ 12:00 AM ] - WOPRAI
Mon, March 28, 2016 Jason West Maintained (ACAD) at Hold with Decreased Target to $22 on, Feb 28th, 2023
Jason West of JMP Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $24 to $22 on, Feb 28th, 2023.
Jason has made no other calls on ACAD in the last 4 months.
There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $17 on, Wednesday, February 15th, 2023
- Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
- Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022
These are the ratings of the 2 analyists that currently disagree with Jason
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
- Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
